一、中文名称：Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody(PHK13901)，司美格鲁肽抗体
二、产品描述
司美格鲁肽是一种新型的长效胰高糖素样肽-1受体激动剂（glucagon-like peptide-1 receptor agonist，GLP-1RA），其结构与天然的人胰高糖素样肽-1（glucagon-like peptide-1，GLP-1）相似，具有高达94%的氨基酸序列同源性，用于成人2型糖尿病患者的血糖控制。
2017年12月在美国获得批准上市，2021年4月中国批准上市，已经在50多个国家和地区获批应用。司美格鲁肽是第6个上市的GLP-1RA药物，是第3个每周1次的长效GLP-1RA类降糖药。司美格鲁肽通过GLP-1受体起作用，可选择性地结合并激活GLP-1受体，刺激胰岛素分泌和降低胰高血糖素分泌的机制来降低血糖，和传统的GLP-1RA比较，其半衰期延长至7d。
2024年6月，用于长期体重管理的胰高糖素样肽﹣1受体激动剂（GLP-1RA）周制剂司美格鲁肽（商品名：诺和盈）在中国大陆获批上市，用于在控制饮食和增加体力活动的基础上对成人患者的长期体重管理。11月17日，诺和诺德宣布诺和盈正式在中国上市。
三、产品详情
名称：Anti-Semaglutide (GLP-1 analogue) Polyclonal Antibody (PHK13901)
别名：Sermaglutide, Semaglutide fandachem, Semaglutide impurity, Sermaglutide USP/EP/BP, semaglutide, Sermaglutide
货号：PHK13901
种属反应性：Human
宿主：Rabbit
同种型：IgG
克隆类型：Polyclonal
免疫原：Synthesized Semaglutide (GLP-1 analogue) conjugated with Carrier protein.
经测试应用：ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
靶标：Sermaglutide, Semaglutide fandachem, Semaglutide impurity, Sermaglutide USP/EP/BP, semaglutide, Sermaglutide, 910463-68-2
浓度：1.28 mg/ml
纯化方式：Purified by antigen affinity column.
Accession号：CAS: 910463-68-2
应用：ELISA, IHC, WB
状态：Liquid
保存溶液：0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
四、参考文献：
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. PMID: 33068776
GLP-1 receptor agonists and cardiovascular outcome trials: An update. PMID: 30528435
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. PMID: 38286487
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. PMID: 34911560
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). PMID: 30944040
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. PMID: 34015974
Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. PMID: 32910487
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. PMID: 37952217
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. PMID: 38316982
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. PMID: 38079178
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. PMID: 32987188
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. PMID: 37684186
Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. PMID: 29915923
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. PMID: 38113888
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? PMID: 30156747
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. PMID: 35838946
Liraglutide and obesity: a review of the data so far. PMID: 25848222
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. PMID: 37409733
Semaglutide for the treatment of obesity. PMID: 34942372
Once-Weekly Semaglutide in Adolescents with Obesity. PMID: 36947474
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID: 33667417
Wegovy (semaglutide): a new weight loss drug for chronic weight management. PMID: 34706925
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. PMID: 36578889
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. PMID: 33755728
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. PMID: 35015037
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 37385278
Semaglutide lowers body weight in rodents via distributed neural pathways. PMID: 32213703
Semaglutide (Ozempic) for weight loss. PMID: 33830968
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.antibodysystem.com/product/17748.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
